HSA
BPMC

Hussman Strategic Advisors’s Blueprint Medicines BPMC Stock Holding History

Hussman Strategic Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,200
Closed -$637K – 323
2021
Q3 		$637K Hold
6,200
– – 0.14% 215
2021
Q2 		$545K Buy
+6,200
New +$568K 0.11% 253

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Hussman Strategic Advisors's BPMC Position: Q4 2021 in Review

Hussman Strategic Advisors sold out of Blueprint Medicines (BPMC) in Q4 2021, closing a stake of 6,200 shares — an estimated $637K sold.

Hussman Strategic Advisors first reported a position in BPMC in Q2 2021 and held it in 2 quarters. The position peaked at $637K in Q3 2021. 280 funds tracked by Wall St. Rank hold BPMC as of Q4 2021.

  • Hussman Strategic Advisors reported no remaining Blueprint Medicines position as of Q4 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 6,200 Blueprint Medicines shares in Q4 2021, an estimated $637K.
  • Hussman Strategic Advisors first reported a position in Blueprint Medicines in Q2 2021 and held it in 2 quarters.
  • Hussman Strategic Advisors's Blueprint Medicines position peaked at $637K in Q3 2021.
  • 280 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2021.

Based on Hussman Strategic Advisors's 13F filing for Q4 2021, filed 31 Jan 2022.